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Abstract
Background: Parkinson's disease (PD) is the second most common neurodegenerative disorder.
Recently, mutations in the PINK1 (PARK6) gene were shown to rarely cause autosomal-recessively
transmitted, early-onset parkinsonism. In order to evaluate whether PINK1 contributes to the risk
of common late-onset PD we analysed PINK1 sequence variations. A German (85 patients) and a
Norwegian cohort (90 patients) suffering from late-onset PD were screened for mutations and
single nucleotide polymorphisms (SNPs) in the PINK1  gene. Both cohorts consist of well-
characterized patients presenting a positive family history of PD in ~17%. Investigations were
performed by single strand conformation polymorphism (SSCP), denaturating high performance
liquid chromatography (DHPLC) and sequencing analyses. SNP frequencies were compared by the
χ2 test
Results: Several common SNPs were identified in our cohorts, including a recently identified
coding variant (Q115L) in exon 1. Genotyping of the Q115L variation did not reveal significant
frequency differences between patients and controls. Pathogenic mutations in the PINK1 gene were
not identified, neither in the German nor in the Norwegian cohort.
Conclusion: Sequence variation in the PINK1 gene appears to play a marginal quantitative role in
the pathogenesis of the late-onset form of PD, in German and Norwegian cohorts, if at all.
Background
PD is the second most common neurodegenerative disor-
der after Alzheimer disease affecting more than 1% of the
population by the age of 65 years. Mutations in the alpha-
synuclein  (PARK1),  Parkin  (PARK2) and DJ-1  (PARK7)
gene cause fairly rare familial forms of PD characterized
by an early age of onset. Mutations in the recently identi-
fied LRRK2 (PARK8) gene, especially the common muta-
tion G2019S, occur more frequently in patients suffering
from early as well as late-onset PD [1,2]. Recently, muta-
tions in the PINK1 (PARK6) gene were shown to cause
autosomal recessively transmitted early-onset parkinson-
ism [3,4]. The PINK1 (PTEN-induced kinase 1) gene
encodes a putative protein kinase. The protein is targeted
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to mitochondria and shows a serine-threonine kinase
domain with homology to kinases of the Ca2+/calmodu-
lin family[3]. It appears to exert protective effects against
cellular stress within mitochondria[3]. These findings link
mitochondria directly to the pathogenesis of PD [3,5]. An
additional link between mitochondrial dysfunction and
PD is obvious via the identification of disease causing
mutations in the Omi/HtrA2 gene [6]. The hypothesis of
mitochondrial impairment was further emphasized by
postmortem studies of PD brains [7] and observation of
PD syndromes after intoxication with mitochondrial
complex I inhibitors, such as MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine) and rotenone [8]. Mutations
in the PINK1 gene are the second most common cause of
autosomal-recessively inherited early-onset PD after
mutations in the Parkin gene. On the other hand, strong
evidence was reported for a possible role of Parkin gene
variations in the late-onset form of PD (age of onset >45
years): Parkin mutations appear to contribute to the com-
mon late-onset form and mutations, especially in exon 7
in heterozygous state, may play a role as susceptibility
alleles for sporadic PD[9,10]. The question arises as to
whether the PINK1 gene is also a candidate gene for late-
onset forms of Parkinson's disease, similar to the sug-
gested role of the Parkin gene.
Here we report of a population-based analysis of sequence
variations within the PINK1  gene. The German cohort
includes 85 patients suffering from late-onset form of PD
and represents a modern urban population with a genetic
heterogeneity. In contrast, the Norwegian cohort repre-
sents a more homogeneous population [11] and includes
90 patients suffering from late-onset form of PD.
Results
All 8 coding exons of the PINK1 gene were screened for
sequence variation using SSCP and sequencing analyses.
Several SNPs were identified in our cohorts (L63L, Q115L,
Ivs4-5A>G het, Ivs6+43C>T het, N521T, c.1783A>T).
Allelic frequencies of several SNPs differed significantly
between the two European cohorts confirming homoge-
neity of the Norwegian cohort (Table 1). Patients and con-
trols were genotyped for the recently identified variation
Q115L [12] using DHPLC analysis (Table 2). The
observed frequencies did not differ significantly between
patients and controls, neither in the German (p = 0.27)
nor in the Norwegian cohort (p = 0.8). This screening did
not reveal any disease-relevant mutation in our cohorts.
Discussion
As recently shown, mutations in the PINK1 gene rarely
cause autosomal-recessively transmitted PD [3]. Besides
an early age of onset, the observed clinical symptoms in
PD caused by PINK1 are similar to symptoms in idio-
pathic PD.
In this population-based study, we investigated whether
sequence variations in the PINK1 gene play a role in the
late-onset form of PD. A recently described variation
(Q115L) of the PINK1 gene [12] was identified in the Ger-
man and the Norwegian cohorts. We calculated allele fre-
quencies in cases and controls and show here that the
Q115L variant was not associated with late-onset PD in
our study. These findings correspond to previously pub-
lished data of no leading association of other coding SNPs
within the PINK1 gene and PD [13]. In addition, several
common SNPs were identified. We did not find any path-
Table 1: Allelic frequencies of identified SNPs in Norwegian (NW) and German (G) patient cohorts
Exon Sequence variation Allelic frequencies p-value *distribution is 
significant
NW G
1 Q115L 0.072 0.035 0.13
1 L63L 0.083 0.218 0.0004 *
5 Ivs4-5A>G 0.017 0.091 0.002 *
6 Ivs6+43C>T 0.041 0.102 0.029 *
8 N521T 0.128 0.188 0.13
8 c.1783A>T 0.201 0.2 0.98
Table 2: Genotyping of the Q115L variation










Q115 (Wildtype) 80 118 0.8 79 190 0.27
Q115L 7 18 6 16
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ogenic mutation of the PINK1 in our cohorts composed of
patients suffering from late-onset form of PD. The risk to
miss potential mutations was minimized by a well estab-
lished and optimized SSCP analyses.
The most likely reason to explain the absence of muta-
tions in our cohorts is the lack of influence of the PINK1
gene in the pathogenesis of late-onset PD. Individual tag-
ging SNPs and tag-defined haplotypes in 500 PD patients
likewise did not reveal associations with PD [14]. Future
investigations should include screening of potential pro-
moter as well as enhancer/silencer regions of the gene to
finally exclude any lack of influence of PINK1 variation on
PD manifestation. Yet, functional investigations of the
PINK1 protein are necessary to identify potential interac-
tion partners as candidates for additional mutation
screening.
Conclusion
Investigations of other genes involved in the mitochon-
drial pathway of the PINK1 gene are necessary to evaluate




The Norwegian cohort (n = 90) consists of patients suffer-
ing from late-onset PD (median age of onset 64.4 years,
range from 49 to 78 years, standard deviation 7.9) origi-
nated from the Stavanger area of Western Norway. This
population is known to be genetically quite homogene-
ous [11] and has previously been described in several clin-
ical PD studies [15,16]. 16.7% of the patients presented a
positive family history for PD concerning first degree rela-
tives (siblings or parents). All patients meet the criteria for
PD [15,17] and were thoroughly clinically examined. An
ethnically matched control group of healthy blood
donors was recruited in Bergen, Norway. The German
cohort (n = 85) consists of patients of the Ruhr area suf-
fering from late-onset PD (median age of onset 58.7 years,
range from 45 to 79 years, standard deviation 8.7) diag-
nosed according to the UK Brain Bank criteria [18]. 16.5%
of the patients presented a positive family history for PD
concerning first degree relatives (siblings or parents). Eth-
nically matched control samples from senior healthy
blood donors (median age 57.2 years, range from 42 to 68
years, standard deviation 5.7) were recruited at the neigh-
bouring University Hospital of Essen (Germany). Popula-
tion stratification was excluded for the controls by
multiple microsatellites analyses. After receiving informed
consent from the patients, peripheral blood samples were
taken and genomic DNA was extracted following standard
protocols. German (Bochum and Düsseldorf) and Norwe-
gian (Bergen) ethics committees approved this study.
SSCP, DHPLC, sequencing
The 8 coding exons of the PINK1 gene were amplified by
polymerase chain reaction (PCR) in all patients using
designed primer pairs adapted to the SSCP technique
(Table 3). SSCP analysis according to standard procedure
[19] was used to identify mutations and SNPs. In order to
optimize mutation screening by SSCP analyses, PCR prod-
ucts were digested with different restriction enzymes
depending on the lengths of their fragments [19] and
screened in two different conditions. Selected samples
with band shifts evidenced in SSCP analyses were con-
firmed by direct sequencing. The sequence reactions were
run on an automated DNA sequencer (Applied Biosys-
tems 377 XL, Foster City, USA) and analyzed with the ABI
Prism™ 377 XL collection and convenient sequencing
analysis software. SNP frequencies of the Q115L variation
in patients and controls were determinated by using
DHPLC analyses (WAVE® system, Cheshire, UK, using
software Wavemaker 4.1) according to established proce-
dures.
Statistical analyses
SNP frequencies were compared by the χ2 test. We consid-
ered P-values < 0.05 as significant.
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Table 3: Primers for PINK1 gene analysis
Exon Primer sequence Product 
size (bp)
Ex 1 F 5'-AAGTTTGTTGTGACCGGCG-3'
R 5'-CTTAGCTCCGTCCTCCGCT-3'
507
Ex 2 F 5'-CCTTCCTAGGCTCCCTGGC-3'
R 5'-AAGATGGGCATTTTGAGAACATCT-3'
387
Ex 3 F 5'-GCTTACAAGGAACTTACCATTCTGC-3'
R 5'-GTGCTGAGGACATAAGTGATGGAT-3'
240
Ex 4 F 5'-GATGTATCAGCTCCAGGCCCT-3'
R 5'-TATTCTTTCCAGGTGTTGTATCTGATG-3'
286
Ex 5 F 5'-AAACGTATTGGGAGTCGTCGA-3'
R 5'-CTCTAGTGCCCCTGGAGAGCT-3'
266
Ex 6 F 5'-CGAGTCTCCTGCATTCAGTGG-3'
R 5'-GACATAGCAGGGCCTCTCAGAG-3'
265
Ex 7 F 5'-TCAGGTGATGTGCAGGACATG-3'
R 5'-CAGAGGTTTCTACCCACACCG-3'
358
Ex 8 F 5'-GGACCAGAGAAGGGAAGACCC-3'
R 5'-TCACGACACAGAGGATGCCA-3'
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